|Bid||329.88 x 1800|
|Ask||330.13 x 900|
|Day's Range||327.38 - 330.53|
|52 Week Range||249.17 - 388.67|
|Beta (3Y Monthly)||1.53|
|PE Ratio (TTM)||23.41|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy. Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016.
Sarepta Therapeutics (SRPT) is working with several strategic partners for developing multiple treatment approaches to DMD. These partners include Nationwide Children’s Hospital, Myonexus, Genethon, Duke University, and Summit Limited.
Sarepta Therapeutics’ (SRPT) Exondys 51 uses exon-skipping technology to skip exon 51 of the DMD gene. The drug is designed to bind to exon 51, which leads to an exclusion or skipping of this exon during mRNA processing. Golodirsen uses exon-skipping technology to skip exon 53 of the DMD gene.
Sarepta Therapeutics’ (SRPT) cost of sales increased from $506,000 in the second quarter of 2017 to $6.73 million in the second quarter. Sarepta’s cost of sales primarily consists of inventory costs, overhead costs, and royalty payments to BioMarin Pharmaceutical (BMRN). These royalty payments resulted from the settlement and licenses agreements in July 2017. Sarepta Therapeutics’ gross income increased from $34.48 million in the second quarter of 2017 to $66.8 million in the second quarter.
On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x. Its forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple, a capital-structure-neutral valuation measure, is 10.4x, which is higher than the industry average of 9.4x. A company’s forward PE ratio reflects the market’s views in regards to the company’s growth potential over the next 12 months.
Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.
Wall Street analysts expect Celgene to report a net income and EPS of $1.2 billion and $1.71, respectively, in the third quarter.
Neurocrine Biosciences’ (NBIX) revenues grew from $6.3 million in the second quarter of 2017 to $96.9 million in the second quarter. The company reported net revenues of $168.0 million in the first half of this year, which grew from $6.3 million in the first half of 2017. Wall Street analysts expect Neurocrine Biosciences to generate revenues of $151.8 million in the third quarter.
Biogen (BIIB) and Eisai have collaborated to jointly develop and commercialize therapies for Alzheimer’s disease. Eisai took the lead in co-developing a BACE inhibitor, elenbecestat, and an anti-amyloid beta protofibril antibody, BAN2401. Biogen took the lead in co-development of an anti-amyloid beta antibody, aducanumab.
The best mutual funds have been heavily buying medical, transportation and retail stocks recently, with CVS, Biogen and Lowe's among the recipients.
A former Biogen Inc. employee has filed a lawsuit accusing the company of failing to accommodate his Parkinson's disease — even as it was developing a drug for the condition. In the suit, which was filed in federal court late last month, Norwood resident and former IT staff member Aldrin Carao claims that Biogen (Nasdaq: BIIB) discriminated against him and backtracked on accommodations it had made for his disease before abruptly firing him in February 2016. Meanwhile, Carao says, the Cambridge biotech was developing a drug for early Parkinson's disease.
Allergan’s (AGN) product portfolio includes generic pharmaceutical products and specialty pharmaceutical products. The company’s business comprises three segments—US General Medicines, US Specialized Therapeutics, and International. The chart below compares Allergan’s revenues and EPS since the first quarter of 2017, as well as its estimates for the third quarter.
The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy. THE GLOBE AND MAIL ** Canadian children with a rare and ...
Ionis Pharmaceuticals (IONS), a leading biopharmaceutical company, has developed a variety of drugs for the treatment of life-threatening diseases through its broadly applicable drug discovery platform. Ionis reported earnings per share of -$0.29 on revenues of $117.7 million during the second quarter, reporting year-over-year growth of 5.0% during the quarter. The chart below compares the company’s revenues since the first quarter of 2017.
Swiss drugmaker Roche (ROG.S) is breaking into hemophilia A treatment, a $10 billion (£7.70 billion) global market dominated by rivals who have cultivated close ties to sufferers of the genetic bleeding disorder. Roche's Hemlibra, on sale since late 2017 for patients with resistance to existing treatments, is widely expected to win the U.S. Food and Drug Administration's blessing for use in nearly all patients this week. To hit $5 billion global annual sales that some analysts forecast, Hemlibra must wrest business away from hemophilia giants like Shire (SHP.L), Bayer (BAYGn.DE), Novo Nordisk (NOVOb.CO) and Octapharma, whose "clotting factors" are now standard for people who lack proteins that stop bleeding.
Health care stocks posted major gains in the latest quarter, leaving many other sectors in the dust. Performance like that has propelled the S&P 500 health care ETF ( XLV) upward by 13% year-to-date (YTD) through Monday's close, compared to the broader S&P 500's 9.4% return over the same period, as industry players such as Biogen Inc. ( BIIB), Eli Lilly and Co. ( LLY) and Pfizer Inc. ( PFE) drive the sector's outperformance. Healthcare bulls expect electoral results to favor the outlook for policies beneficial to a wide range of healthcare related companies.
It announced a first-quarter interim dividend of $0.5625 on December 11, 2017. It announced a second-quarter interim dividend of $0.5625 on May 8, 2018. It announced a third-quarter interim dividend of $0.5625 on June 18, 2018.
The S&P 500 health-care sector has been on a tear in recent months, on track for its best quarter in five years and surging to an all-time high on Friday. Names such as Eli Lilly, Biogen and Pfizer are ...
On September 12, Allergan (AGN) announced the launch of SpotLyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit. On September 6, Allergan announced the launch of its dual-acting product, the SkinMedica Lumivive System. SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.
Allergan (AGN) is a specialty pharmaceutical company focused on organic as well as inorganic growth methods. The chart below highlights several recent developments for Allergan.
Biotechnology is considered one of the most dynamic and profitable sectors, where investment in research and development is necessary for survival. Biogen Inc. (NASDAQ:BIIB) is one of the leading players in this sector, with a proven track record in neurological and neurodegenerative diseases. The company has a strong portfolio of drugs catering to diseases like multiple sclerosis, Alzheimer's, dementia and neuromuscular disorders.